mileston
wider net loss current cash suffici note
key focu area advanc avapritinib toward registr
defin path expand pipelin optim
discoveri platform advanc two new candid develop strateg
partnership anticip mileston continu posit news
flow like support higher valuat view
wider net loss vs loss estimate larg lower revenu
vs due termin alexion hold agreement
in-lin opex vs suffici
lead candid avapritinib initi pivot studi gist
 asm track potenti first regulatori file estim
pdgfra gist addit pt enrol track complet
 follow-up togeth pdgfra gist
plan file approv kit-driven gist expand enrol pt
averag patient expect occur kit-driven
gist track start avapritinib vs regorafenib kit-driven
gist enrol pt avapritinib sm start pivot
advanc sm asm dose finding/poc indolent/smold sm
addit clinic data updat asm like eha
key clinic data ret inhibitor either
comment efficaci
expect dose-escal studi ret-alt nsclc/thyroid/oth
advanc solid tumor discuss indic respons like seen tumor
fusion common fusion partner nsclc
suggest less suscept ret inhibit show
recist respons although orr fusion
pt increas larg base time laps discount
year adjust opex alloc npv product
pt base gist/asm
nsclc/mtc collabor risk incl clinic risk competit
pleas see analyst certif import disclosur inform inform regard statu non-u analyst page report
upcom catalyst includ initi tki-nav cohort trial
engag regulatori author path registr avapritinib
gist asm initi registration-en studi avapritinib
gist asm present data trial ret-alt
cancer initi expans initi ind-en studi
fop complet enrol registration-en trial avapritinib
pdgfra gist start trial indolent/smold sm
releas initi data tki-nav
nomin least addit discoveri program
compani report jefferi
page
pleas see import disclosur inform page report
productdescriptionindicationstatusmarket rightspat expirygastrointestin stromal tumor gist initi kitm gist voyag compar avapritinib vs regorafenib random primari endpoint explor expedit clinic develop pathwa kit-driven gist regulatori author pursu acceler approv pdgfr base fda feedback expand enrol complet expand on-going patient ad new cohort gistaddit data updat data cutoff kit pdgfra median prior tki use kit gist regorafenib pdgfra gist dosag qd potenti intra-pati escal pt ae grade discontinu ae add discontinu progress diseas withdrew consent qd kit pt tumor reduct across common kit mutant median mo mrecist pr orr histor orr median mo imatinib pdgfr pt dose w/ tumor reduct cr pr sd orr dcr median reach histor orr mo median w/ imatinib blueprintsystem mastocytosi registration-en studi advanc sm asm start follow regulatori discuss addit data explor releas dose escalation/poc trial indolent/smold sm begin part dose find lower dosag vs asm part random placebo-control endpoint patient report outcomesat show orr asm vs midostuarin orr iwg-mrt-ecnm median tx durat mo rang mo pt grade treatment-rel occur pt neutropenia discontinu due drug-rel enrol pt part expans portion molecul inhibitorhepatocellular carcinoma ad tx-naiv cohort initi data explor io combinationa cut-off evalu pt orr incl tki-naiv patient orphan drug design com patent expir pend patent would expir molecul target retsolid cancer includ nsclc medullari thyroid solid data initi expans expand pt enrol first pt enrol blueprintpend patent applic would expir target activin receptor-lik kinas mutationfibrodysplasia ossifican progressiva fop initi ind-en studi plan present preclin data priorit program vs evalu option advanc preclin activ follow discontinu collabor alexion blueprint-undisclosedtwo undisclos kinas targetsundiscloseda wholli own program research portfolio two undisclos kinas target blueprint-roch collaborationsmal molecul therapeuticscanc immunotherapyent collabor licens agreement roch three identifi target two program began third expect begin target prkacafibrolamellar carcinoma flc de-priorit programpreclin discoveri announc program maximum toler dose recommend phase dose immunohistochemistri fish fluoresc situ hybrid pdgfr platelet-deriv growth factor receptor alpha fibroblast growth factor receptor nsclc non-smal cell lung cancer prkaca protein kinas camp-activ catalyt subunit alpha fibroblast growth factor overexpressingproprietari programspartn programsavapritinib molecul inhibitor kit exon pdgfr mutationsfda orphan drug design grant gist sm jan issu com patent expir pend patent would expir grant
compani report jefferi
page
pleas see import disclosur inform page report
salesavapritinib gist- growth asm- growth hcc- growth nsclc growth royaltiesavapritinib gist- growth asm- growth hcc- growth nsclc growth growth good sold gross growth growth expens incom loss oper growth incom loss tax benefit tax incom loss incom loss common stockhold ep lp ep lp growth basic share cash equival thousand except per share incom statementblueprint medicin corpor
blueprint medicin corpor incorpor delawar headquart cambridg biopharmaceut compani
identifi develop small molecul kinas inhibitor focus rare diseas three drug candid phase
develop kit exon pdgfr mutant inhibitor gastrointestin stromal tumor gist adult system
mastocytosi sm inhibitor liver cancer hepatocellular carcinoma ret inhibitor non-smal cell
lung cancer nsclc medullari thyroid cancer mtc solid tumor use kinas discoveri engin compound librari
enter collabor licens agreement roch march
eun yang ph certifi view express research report accur reflect person view subject secur
subject compani also certifi part compens directli indirectli relat specif recommend
view express research report
scott puckhab certifi view express research report accur reflect person view subject
secur subject compani also certifi part compens directli indirectli relat specif
recommend view express research report
case jefferi employe analyst respons coverag financi instrument discuss report receiv
compens base part overal perform firm includ invest bank incom seek updat research
appropri variou regul may prevent us asid certain industri report publish period basi larg major
report publish irregular interv appropri analyst judgement
articl articl
